100 related articles for article (PubMed ID: 15088017)
1. Cancer myths. Setting the record straight.
Mayo Clin Womens Healthsource; 2004 Apr; 8(4):1-2. PubMed ID: 15088017
[No Abstract] [Full Text] [Related]
2. Setting the record straight: five cancer myths debunked. Cancer experts talk about the most common cancer myths--and why they are erroneous.
Health News; 2006 Feb; 12(2):7-8. PubMed ID: 16453936
[No Abstract] [Full Text] [Related]
3. Dual-action drug approved for use in advanced breast cancer.
McBride D
ONS Connect; 2007 Jun; 22(6):19. PubMed ID: 17598617
[No Abstract] [Full Text] [Related]
4. Lessons learned from independent central review.
Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
[TBL] [Abstract][Full Text] [Related]
5. Vaccine approved for prostate cancer. The vaccine, which harnesses the immune system, may provide more treatment options for all cancers.
Duke Med Health News; 2010 Jul; 16(7):3. PubMed ID: 20662142
[No Abstract] [Full Text] [Related]
6. Translation of cancer immunotherapies.
Mulé JJ; Weber JS
Nat Med; 2004 Nov; 10(11):1153; author reply 1153-4. PubMed ID: 15516900
[No Abstract] [Full Text] [Related]
7. Barriers to efficient development of cancer therapeutics.
Schein PS; Scheffler B
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3243-8. PubMed ID: 16740743
[No Abstract] [Full Text] [Related]
8. Translation of cancer immunotherapies.
Skipper J; Hoffman EW; O'Donnell-Tormey J; Old LJ
Nat Med; 2004 Nov; 10(11):1154-5; author reply 1155. PubMed ID: 15516901
[No Abstract] [Full Text] [Related]
9. Cancer drug approval in the United States, Europe, and Japan.
Milsted RA
Adv Cancer Res; 2007; 96():371-91. PubMed ID: 17161686
[No Abstract] [Full Text] [Related]
10. Researchers left to guess at outcomes of most cancer clinical trials.
Twombly R
J Natl Cancer Inst; 2009 Jan; 101(2):72-4. PubMed ID: 19141774
[No Abstract] [Full Text] [Related]
11. Multifunctional vaccines in cancer: the 'triad' approach.
Nemunaitis J
Expert Rev Vaccines; 2011 Jun; 10(6):713-5. PubMed ID: 21692693
[No Abstract] [Full Text] [Related]
12. Business barriers slowing the pace of cancer immunotherapy research and development.
Tuma RS
J Natl Cancer Inst; 2007 Nov; 99(21):1570-3. PubMed ID: 17971521
[No Abstract] [Full Text] [Related]
13. Setting the record straight on PDR criticisms.
Mehta M
Postgrad Med; 2000 Jan; 107(1):22. PubMed ID: 10649658
[No Abstract] [Full Text] [Related]
14. FDA likely to further restrict erythropoietin use for cancer patients.
Fox JL
Nat Biotechnol; 2007 Jun; 25(6):607-8. PubMed ID: 17557084
[No Abstract] [Full Text] [Related]
15. The ODAC Chronicles: Part 3. The FDA's philosophy and process for cancer drug evaluation and approval.
Grillo-López AJ
Expert Rev Anticancer Ther; 2005 Feb; 5(1):1-5. PubMed ID: 15757431
[No Abstract] [Full Text] [Related]
16. Targeted agents: the rules of combination.
Kwak EL; Clark JW; Chabner B
Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5232-7. PubMed ID: 17875749
[TBL] [Abstract][Full Text] [Related]
17. Cancer therapies crisis in the USA.
Grillo-López AJ
Expert Rev Anticancer Ther; 2003 Oct; 3(5):579-82. PubMed ID: 14599082
[No Abstract] [Full Text] [Related]
18. Cancer drugs. Weighing the risks and benefits.
Bren L
FDA Consum; 2007; 41(1):10-9. PubMed ID: 17342832
[TBL] [Abstract][Full Text] [Related]
19. The US Food and Drug Administration Cardiorenal Advisory Panel and the drug approval process.
Roden DM; Temple R
Circulation; 2005 Apr; 111(13):1697-702. PubMed ID: 15811869
[No Abstract] [Full Text] [Related]
20. Can the U.S. Food and Drug Administration act against global frauds? The extraterritorial effect of Food and Drug Administration sanctions after Small v. United States.
O'Reilly J
Food Drug Law J; 2005; 60(3):347-60. PubMed ID: 16304742
[No Abstract] [Full Text] [Related]
[Next] [New Search]
